RRA-17401, Risperidone Exposure and the Risk of Osteoporosis-related Fractures – Taiwan

Study identification

• EU PAS number:
  EUPAS20730
• Study ID:
  24441
• Official title and acronym:
  RRA-17401, Risperidone Exposure and the Risk of Osteoporosis-related Fractures – Taiwan
• DARWIN EU® study:
  No
• Study countries:
  Taiwan
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

Kaohsiung Municipal Kai-Syuan Psychiatric Hospital

Study timelines

Date when funding contract was signed

Actual:01/04/2015

Study start date

Actual:01/06/2015

Date of final study report

Actual:21/02/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Janssen Research & Development (JRD)

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  EU RMP category 3 (required)